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Abstract		
Background	
Hydration	in	advanced	cancer	is	a	controversial	area;	however,	current	hydration	
assessments	methods	are	poorly	developed.	Bioelectrical	impedance	vector	analysis	(BIVA)	
is	an	accurate	hydration	tool;	however	its	application	in	advanced	cancer	has	not	been	
explored.	This	study	used	BIVA	to	evaluate	hydration	status	in	advanced	cancer	to	examine	
the	association	of	fluid	status	with	symptoms,	physical	signs,	renal	biochemical	measures	
and	survival.	
Materials	and	methods	
An	observational	study	of	90	adults	with	advanced	cancer	receiving	care	in	a	UK	specialist	
palliative	care	inpatient	unit	was	conducted.	Hydration	status	was	assessed	using	BIVA	in	
addition	to	assessments	of	symptoms,	physical	signs,	performance	status,	renal	biochemical	
measures,	oral	fluid	intake	and	medications.	The	association	of	clinical	variables	with	
hydration	was	evaluated	using	regression	analysis.	A	survival	analysis	was	conducted	to	
examine	the	influence	of	hydration	status	and	renal	failure.		
Results	
The	hydration	status	of	participants	was	normal	in	43	(47.8%),	'more	hydrated'	in	37	(41.1%)	
and	'less	hydrated'	in	10	(11.1%).	Lower	hydration	was	associated	with	increased	symptom	
intensity	(Beta	=	-0.29,	p=0.04)	and	higher	scores	for	physical	signs	associated	with	
dehydration	(Beta	=	10.94,	p=0.02).	Higher	hydration	was	associated	with	oedema	(Beta	=	
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2.55,	p<0.001).	Median	survival	was	statistically	significantly	shorter	in	'less	hydrated'	
patients	(44	vs.	68	days;	p=0.049)	and	in	pre-renal	failure	(44	vs.	100	days;	p=0.003).	
Conclusions	
In	advanced	cancer,	hydration	status	was	associated	with	clinical	signs	and	symptoms.	
Hydration	status	and	pre-renal	failure	were	independent	predictors	of	survival.	Further	
studies	can	establish	the	utility	of	BIVA	as	a	standardised	hydration	assessment	tool	and	
explore	its	potential	research	application,	in	order	to	inform	the	clinical	management	of	
fluid	balance	in	patients	with	advanced	cancer.	
Key	words	
Palliative	care;	cancer;	hydration;	dehydration;	bioelectrical	impedance	analysis;	clinically	
assisted	hydration;	renal	failure;	technology;	end	of	life.	
Key	message	
Bioelectrical	impedance	vector	analysis	(BIVA)	was	used	to	study	the	hydration	status	of	
individuals	with	advanced	cancer,	in	order	to	determine	the	relationship	of	hydration	with	
symptoms,	physical	signs,	renal	biochemical	measures	and	survival.	The	findings	
demonstrate	that	hydration	in	advanced	cancer	was	significantly	associated	with	physical	
signs,	symptoms	and	oral	fluid	intake.	Survival	was	statistically	significantly	shorter	in	‘less-
hydrated’	individuals	and	those	with	pre-renal	failure.	The	findings	demonstrate	the	
potential	to	use	BIVA	to	evaluate	hydration	in	advanced	cancer.	
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Introduction	
People	with	advanced	cancer	commonly	experience	reduced	oral	intake	in	the	last	days	of	
life.[1]	This	may	cause	healthcare	professionals	and	family	caregivers	to	question	whether	
clinically	assisted	hydration	(CAH)	is	required	for	the	management	of	hydration	status	and	
symptoms.	However,	there	is	limited	evidence	to	determine	the	association	between	
hydration	and	symptoms	in	advanced	cancer.[2]	Physical	examination	has	low	sensitivity	
and	specificity	for	identifying	fluid	deficit.[2,	3]	The	evidence	for	the	use	and	effects	of	CAH	
in	advanced	cancer	is	limited,	conflicting	and	inconclusive.[2,	4,	5]	
Bioelectrical	impedance	analysis	(BIA)	is	a	non-invasive	body	composition	assessment	tool	
based	on	the	flow	of	electrical	current	through	the	body.[6]	The	recorded	measurements	
include:	resistance	(R	-	the	restriction	to	the	flow	of	electrical	current	through	the	body,	
primarily	related	to	the	amount	of	water	present	in	tissue)	and	reactance	(Xc	-	resistive	
effect	produced	by	the	tissue	interfaces	and	cell	membranes).	BIA	technology	has	been	used	
to	evaluate	hydration	and	nutrition	in	various	populations.[2,	7]	The	impedance	index	
(Height	-	H	(m)2/R	(Ohms))	is	the	best	single	predictor	of	total	body	water	(TBW)	in	
validation	studies,	including	cancer	populations.[8-19]		
The	BIA	vector	analysis	(BIVA)	RXc	graph	method	involves	BIA	measurements	that	are	
standardized	by	height	and	plotted	as	bivariate	vectors	with	their	confidence	intervals	
(which	are	ellipses	on	the	R-Xc	plane).	The	advantage	of	this	method	is	that	it	allows	for	
information	to	be	obtained	simultaneously	about	changes	in	tissue	hydration	or	soft-tissue	
mass,	independent	of	regression	equations,	or	body	weight.	BIVA	has	been	used	to	study	
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hydration	in	a	variety	of	different	diseases[20-28]	and	to	undertake	general	body	
composition	assessments	in	lung	cancer[27,	29]	and	cancers	of	the	head	and	neck.[30]	
Aim	
The	aim	of	this	observational	study	was	to	use	H2/R	and	BIVA	to	study	the	hydration	status	
of	individuals	with	advanced	cancer,	in	order	to	determine	the	relationship	of	hydration	
with	symptoms,	physical	signs,	renal	biochemical	measures	and	survival.		
Materials	and	Methods		
Participants	were	recruited	from	a	UK	specialist	palliative	care	unit	between	December	2012	
and	October	2013.	The	research	project	adhered	to	the	requirements	of	the	UK	Department	
of	Health	Research	Governance	Framework.	Written	consent	was	obtained	from	all	study	
participants;	this	included	consent	to	report	individual	patient	data	in	publication.	
Participant	consent	was	recorded	in	a	research	recruitment	log.	This	study	was	approved	by	
the	North	Wales	Research	Ethics	Committee	–	West	(Local	research	ethics	committee	
approval	number	=	12/WA/0200).	The	eligibility	criteria	for	study	entry	was:	admission	to	
specialist	palliative	care	inpatient	unit;	age	≥18	years;	cancer	(proven	by	histology	or	
radiological	imaging);	palliative	condition	(no	further	curative	treatment	possible);	able	to	
understand	and	communicate	in	English;	serum	urea	and	creatinine	recorded	by	the	clinical	
team	in	the	previous	72	hours.	Our	exclusion	criteria	were:	individuals	with	implantable	
defibrillator	devices;	unable	to	provide	fully	informed	consent;	active	transmissible	
infections;	current	use	of	CAH;	current	antineoplastic	treatment.	
Assessments	
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All	assessments	were	conducted	between	9am	–	12pm.	The	following	information	was	
recorded:	age	(years);	gender;	ethnicity;	cancer	diagnosis	(defined	by	the	International	
Classification	of	Diseases)[31]	and	primary	site	of	cancer.		
Participant	observations	
A	dehydration	score	was	calculated	using	the	approach	of	Morita	et	al,[32]	based	on	a	total	
of	scores	from	three	physical	findings:	oral	mucous	membranes	moisture	(0:	moist,	1:	
somewhat	dry,	2:	dry),	axillary	moisture	(0:	moist,	1:	dry),	and	sunkenness	of	eyes	(0:	
normal,	1:	slightly	sunken,	2:	sunken).	These	signs	have	significant	correlations	with	
biological	dehydration,[33-36]	with	higher	scores	(range	0-5)	indicating	an	increased	risk	of	
dehydration	(previous	studies	have	used	a	Morita	cut-off	of	2	to	define	an	increased	risk	of	
dehydration[37,	38]).	Performance	status	was	recorded	using	the	Eastern	Cooperative	
Oncology	Group	(ECOG)	scale	(0=	fully	active,	5=	dead).[39]	Daily	fluid	intake	(0	-	199mL,	
200-499mL,	500-799	or	>800mLs)	was	recorded	using	nursing	assessments.	Height	was	
measured,	without	shoes,	to	the	nearest	0.1cm	using	a	portable	stadiometer	(SECA	213	
Height	Measure	/	Stadiometer).	Length	was	measured	in	those	unable	to	stand.	Body	
weight	was	measured	to	the	nearest	0.1kg	(SECA	955	High	Capacity	Electronic	Chair	Scale).	
The	following	biochemical	measures	were	recorded:	urea	(mmol/L),	creatinine	(µmol/L),	
estimated	glomerular	filtration	rate	(eGFR)	(mL/min/1.73m2),	serum	sodium	(mmol/L),	
serum	albumin	(g/L),	adjusted	calcium	(mmol/L)	and	urine	osmolality	(mosm/kg).	
Hydration	questionnaire		
Participants	completed	a	hydration	symptom	questionnaire	(Burge-4	score).[36,	40]	This	
comprised	of	four	questions	(thirst,	dry	mouth,	unpleasant	taste	and	fatigue)	measuring	
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symptom	severity	over	the	previous	24-hours	using	a	100mm	Visual	Analogue	Scale	(VAS).	
At	the	time	of	the	study,	the	Burge	questionnaire	was	the	only	available	dehydration	
symptom	assessment	tool	for	advanced	cancer	patients.	
Medication	review	
The	following	medication	information	was	recorded:	the	total	daily	morphine	dose	
(calculated	using	opioid-equivalency	ratios[41,	42]);	use	of	serotonin	reuptake	inhibitors	
(SSRIs);	use	of	serotonin	noradrenaline	reuptake	inhibitors	(SNRIs)	and	diuretics.	The	
Anticholinergic	Burden	(ACB)	scale[43,	44]	was	used	to	calculate	the	potential	
anticholinergic	symptom	burden	from	the	use	of	these	medications.		
Bioelectrical	impedance	assessments	
The	EFG3	ElectroFluidGraph	Vector	Impedance	Analyser	(Akern)	was	used	for	the	BIA	
assessments.	The	method	involved	a	tetra-polar	technique	to	deliver	a	single	frequency	
electrical	current	of	50kHz	(±5%).	The	external	calibration	of	the	analyser	was	checked	daily	
using	an	impedance	calibration	circuit	(R	=	470	Ω,	Xc	=	90	Ω).	The	testing	procedure	was	
conducted	in	line	with	methods	described	by	Lukaski[45]	and	other	recommendations.[46,	
47]	Participants	were	lightly	clothed,	lying	in	the	supine	horizontal	position,	without	shoes	
or	socks.	Their	arms	were	positioned	30	degrees	from	the	body	with	the	legs	positioned	45	
degrees	away	from	each	other.	Two	disposable	pre-gelled	aluminium	electrodes	were	
affixed	to	the	dorsum	of	the	right	hand	(one	placed	on	the	edge	of	an	imaginary	line	
bisecting	the	ulnar	head	and	the	other	on	the	middle	finger	proximal	to	the	metacarpal-
phalangeal)	and	two	to	the	dorsum	of	the	right	foot	(one	placed	medially,	to	an	imaginary	
line	bisecting	the	medical	malleolus	at	the	ankle	and	the	other	proximal	to	the	metatarsal-
phalangeal	joints).	
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BIVA	point	graph	analysis	
For	the	BIVA	method,	the	impedance	vector	(Z)	was	plotted	as	a	bivariate	vector	from	its	
components,	R	(X	axis)	and	Xc	(Y	axis),	after	being	standardized	by	height	(H);	this	forms	two	
correlated	normal	random	variables	(i.e.	a	bivariate	Gaussian	vector).[48,	49]	Elliptical	
probability	regions	of	the	mean	vector	are	plotted	on	the	RXc	plane	forming	elliptical	
probability	regions	on	the	RXc	plane,	which	are	tolerance	ellipses	for	individual	vectors	and	
confidence	ellipses	for	mean	vectors.[6,	49-52]	Tolerance	ellipses	are	the	bivariate	reference	
intervals	of	a	normal	population	for	an	observation.	The	RXc	graph	features	three	tolerance	
ellipses:	the	median,	the	third	quartile,	and	the	95th	percentile	(i.e.	50%,	75%	and	95%	of	
individual	points).	
Participant	data	were	plotted	on	the	RXc	point	graph	using	the	50%,	75%	and	95%	tolerance	
ellipses	from	a	non-cancer	reference	population.[6]	Hydration	status	was	determined	by	the	
individual’s	baseline	bioimpedance	vector	position	on	the	BIVA	RXc	normogram.	The	
normogram	is	a	five-point	graph	(corresponding	with	the	boundaries	of	each	tolerance	
ellipse).	We	simplified	the	normogram	into	three	parallel	sections	for	this	study	(Fig	1).	
Individuals	with	vectors	falling	in	(or	above)	the	51–75%	tolerance	ellipse	(points	1	and	2)	
were	classified	as	‘less-hydrated’.	Participants	with	vectors	in	the	central	50th	percentile	
ellipse	(point	3)	were	classified	as	‘normally-hydrated’.	Those	with	vectors	in	(or	below)	the	
lower	51%	-	75%	percentile	range	(points	4	and	5)	were	classified	as	‘more	hydrated’.	
Participants	were	compared	according	to	their	hydration	status	classification	(‘less	
hydrated’	vs.	‘not	less	hydrated’)	to	evaluate	differences	in	biochemistry,	symptoms,	clinical	
signs	and	fluid	intake.		
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Fig	1.	Classification	of	hydration	status	using	the	RXc	graph	and	the	50th	and	75th	
percentile	tolerance	ellipses		
	
	
	
	
	
	
The	50%	and	75%	percentiles	were	used	to	project	a	5-point	hydration	scale	on	the	BIA	
normogram.	Positions	1	and	2	=	‘less	hydrated’	individuals;	position	3	=	‘normally	hydrated’	
individuals;	positions	4	and	5	=	‘more	hydrated’	individuals.	
	
H2/R	Analysis	
The	H2/R	was	used	as	a	proxy	measure	of	hydration	status	(i.e.	TBW).	Multiple	linear	
regression	analysis	was	conducted	to	further	study	the	relationship	between	several	
predictor	variables	with	the	H2/R.	The	variables	included:	patient	demographics	(age,	
gender),	clinical	measurements	(Morita	Dehydration	Score,	oedema	presence)	serum	
biochemistry	(urea:creatinine	(ur:cr)	ratio)	and	self-reported	symptoms	(Burge-4	score).	Pre-
renal	failure	was	defined	by	a	ur:cr	ratio	of	≥100	(mmol/mmol).	This	biochemical	definition	
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was	chosen	based	on	the	work	of	similar	studies	(NOTE:	as	creatinine	was	recorded	in	
µmol/L	we	divided	this	by	1000	to	convert	to	mmol/L	to	calculate	the	ur:cr	ratio).[3,	53-55]	
A	separate	multiple	linear	regression	analysis	involving	the	Burge-4	score	and	the	assessed	
medications	was	conducted	to	determine	the	potential	influence	of	medications	on	
symptoms.	
Sample	size	calculation	
An	exploratory	sample	of	90	patients	was	chosen	to	achieve	a	minimum	of	10	subjects	for	
each	item	in	the	regression	model.	For	the	RXc	graph,	a	sample	size	of	90	provides	a	95%	
confidence	region	for	the	mean	vector	of	the	vector	random	variable	(Z(R),	Z(Xc))	as	an	
ellipse	with	semi-axes	of	approximate	lengths	of	0.33	and	0.16.	For	the	two-group	analysis,	
a	sample	size	of	45	(for	each	of	the	two	groups)	has	power	of	0.8	for	detecting	a	difference	
of	(0.5,	0.5)	in	the	mean	BIVA	vectors	between	groups,	for	significance	level	of	0.05.[56]		
Statistical	analysis		
The	primary	focus	of	this	study	was	to	use	the	H2/R	and	BIVA	to	evaluate	the	relationship	of	
hydration	status	with	physical	signs,	symptoms,	biochemical	measures	and	survival.	
Statistical	Package	for	the	Social	Sciences	(SPSS)	version	21.0	was	used	for	standard	
calculations.	Distributions	of	all	variables	were	assessed	for	normality	using	the	Shapiro-Wilk	
test.	Parametric	and	non-parametric	tests	were	used	as	appropriate.	Frequency	analysis	was	
conducted	to	compare	differences	between	groups	and	variables	using	the	chi-squared	test,	
Student	t	test	and	the	Mann-Whitney	U	test.	For	the	independent	t-tests,	Levene’s	test	for	
homogeneity	of	variance	was	used	to	examine	the	quality	of	variances	within	a	population	
to	identify	whether	derivatives	required	exclusion	or	separate	analysis	from	the	cohort.	
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Multiple	linear	regression	analysis	was	used	to	evaluate	associations	between	variables.	The	
significance	level	was	set	at	<0.05.	The	BIVA	statistical	analysis	was	conducted	using	
software	developed	by	Professor	Antonio	Piccoli,	University	of	Padova.[57]	Hotelling’s	T2	
test	for	vector	analysis	was	used	to	compare	for	significant	difference	between	mean	vector	
distances.		
Survival	was	evaluated	from	baseline	assessment	to	death.	All	patients	were	followed	up	for	
3-months	following	completion	of	the	study.	Kaplan-Meier	analysis	was	used	to	analyse	
survival,	according	to	the	hydration	status	and	renal	failure	status.	A	Cox	proportional	
hazards	model	was	used	to	assess	the	effect	of	the	ur:cr	ratio	and	the	H2/R	on	survival,	with	
adjustment	for	demographic	characteristics,	baseline	ECOG	performance	status	and	cancer	
type.		
Results		
Demographics	
Ninety	patients	(males	=	42,	46.7%;	females	=	48,	53.3%)	participated	(recruitment	rate	=	
76.3%)	(Fig	2).	The	mean	age	of	participants	was	71.2	years	(SD±	12.21)	and	were	mostly	
Caucasian	(n=89,	98.9%)	(Table	1).	Twenty-one	different	types	of	cancers	(in	addition	to	4	
(4.4%)	unknowns)	were	recorded;	lung	cancer	was	the	most	common	(n=14,	15.6%).	Most	
participants	had	an	ECOG	performance	status	of	3	(n=36,	40%).		
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Fig	2.	Recruitment	flowchart			
	
	
	
	
	
	
	
	
	
	
	
	
Flowchart	representation	of	the	number	of	individuals	recruited	to	the	study.	
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Table	1.	Demographic	details	of	study	participants			
Characteristic	 N	(Data	presented	as	
mean	or	%)	
Mean	age	(±	SD),	years	 71.17	(12.21)	
Male	 42	(46.7)	
Female	 48	(53.3)	
Mean	height	(±	SD),	cm	 164.22	(9.6)	
Mean	weight	(±	SD),	kg	 69.45	(17.9)	
Mean	body	mass	index	(±	SD),	kg/m2	 25.17	(4.98)	
Race/ethnicity	 	
	 Caucasian	 89	(98.9)	
	 Other	 1	(1.1)	
ECOG	 	
	 0:	Asymptomatic		 0	(0)	
	 1:	Symptomatic	but	completely	ambulatory		 15	(16.7)	
	 2:	Symptomatic,	<50%	in	bed	during	the	day	 22	(24.4)	
	 3:	Symptomatic,	>50%	in	bed,	but	not	bedbound	 36	(40.0)	
	 4:	Bedbound	 17	(18.9)	
Cancer	diagnosis	 	
	 Lung	 14	(15.6)	
	 Colorectal	 11	(12.2)	
	 Prostate	 10	(11.1)	
			
14	
	 Ovarian	 6	(6.7)	
	 Breast	 6	(6.7)	
	 Oesophageal	 5	(5.6)	
	 Myeloma	 5	(5.6)	
	 Pancreatic	 4	(4.4)	
	 Unknown	 4	(4.4)	
	 Cervical	 3	(3.3)	
	 Mesothelioma	 3	(3.3)	
	 Gastric	 3	(3.3)	
	 Brain	 3	(3.3)	
	 Melanoma	 2	(2.2)	
	 Soft	tissue/muscle/connective	tissue	 2	(2.2)	
	 Biliary	 2	(2.2)	
	 Lymphoma	 2	(2.2)	
	 Bladder	 1	(1.1)	
	 Liver	 1	(1.1)	
	 Groin	 1	(1.1)	
	 Uterus	 1	(1.1)	
	 Tongue	 1	(1.1)	
Table	1	shows	the	details	of	age,	gender,	height,	weight,	body	mass	index,	performance	
status	and	cancer	diagnosis.		
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Clinical	assessments		
The	baseline	assessments	are	presented	in	Table	2.	Most	participants	had	a	daily	oral	fluid	
intake	of	approximately	500	–	799mLs	(n	=	42,	46.7%).	Pre-renal	failure	was	present	in	37	
(41.1%)	patients	and	mean	eGFR	was	72.1	mL/min/1.73m2.	The	highest	symptom	score	was	
recorded	for	fatigue	(M	=	63.60,	SD	=	30.09).	The	mean	Burge-4	score	was	222.07mm	(SD	=	
95.40)	and	ranged	from	0	to	400mm.	The	Morita	Dehydration	Score	was	≥2	in	52	(57.8%)	
participants.	
	
Table	2.	Study	baseline	results			
Variable	 N	 Mean	
(M)	
SD	 Range	(min	–	
max)	
Normal	reference	range	
(min	–	max)	
Biochemical	results	 	 	 	 	 	
	 Sodium	(mmol/L)	 89	 136.12	 4.28	 126	-	145	 133	-	146	
	 Urea	(mmol/L)	 90	 7.26	 4.36	 1.3	–	33.8	 2.5	-	7.8	
	 Creatinine	(μmol/L)	 90	 79.26	 30.33	 23	-	183	 50	-	130	
	 eGFR	(mL/min/1.73m2)	 90	 72.1	 18.77	 24	-	90	 0-90	
	 Ur:cr	ratio	(mmol/mmol)	 90	 96.68	 53.16	 32.61	–	
383.61	
	
	 Pre-renal	failure:	Ur:cr	ratio	
≥100	(%)	
37	
(41.1)	
	 	 	 	
	 Adjusted	calcium	(mmol/L)	 89	 2.32	 0.24	 1.65	–	3.5	 2.20	-2.60	
	 Serum	albumin	(g/L)	 90	 32.07	 6.08	 3	-	47	 35	-	50	
	 Serum	osmolarity	(mmol/kg)	 61	 286.36	 10.03	 260	-	311	 275	-	295	
	 Urine	osmolarity	(mmol/kg)	 22	 511.77	 202.83	 174	-	951	 250	-	750	
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Bioelectrical	impedance	 	 	 	 	 	
	 R/H	(Ohm/m)	 90	 341.58	 82.22	 	 	
	 Xc/H	(Ohm/m)	 90	 27.68	 9.49	 	 	
	 PA	(degrees)	 90	 4.71	 1.33	 	 	
	 H2/R	(m2/Ohm)	 90	 51.58	 15.41	 	 	
Morita	Dehydration	Score	 	 	 	 	 	
	 <2	(%)	 38	
(42.2)	
	 	 	 	
	 ≥2	(%)	 52	
(57.8)	
	 	 	 	
Burge-4	score	(mm)	 	 	 	 	 	
	 Total	score	(mm)	 90	 222.07	 95.40	 0	-	400	 	
	 Thirst	(mm)	 90	 56.11	 29.49	 0	-	100	 	
	 Dry	mouth	(mm)	 90	 60.01	 30.64	 0	-	100	 	
	 Unpleasant	taste	(mm)	 90	 42.34	 34.11	 0	-	100	 	
	 Fatigue	(mm)	 90	 63.60	 30.09	 0	-	100	 	
Daily	oral	fluid	intake	 	 	 	 	 	
	 0	–	499mLs	(%)	 27	
(30.0)	
	 	
	
	
	 500	–	799mLs	(%)	 42	
(46.7)	
	 	
	
	
	 ≥800mLs	(%)	 21	
(23.3)	
	 	 	 	
Table	2	shows	descriptive	statistics	of	biochemical	results,	bioelectrical	impedance,	physical	
signs	(Morita	Dehydration	Score),	symptoms	(Burge-4	score)	and	daily	oral	fluid	intake.		
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Multiple	linear	regression	analysis	
The	H2/R	was	significantly	predicted	by	female	gender	(Beta	=	-13.85,	p<0.001),	symptoms	
(the	Burge-4	score)	(Beta	=	-0.29,	p=0.04),	physical	signs	(the	Morita	Dehydration	Score)	
(Beta	=	-2.55,	p=0.02)	and	oedema	(Beta	=	10.94,	p<0.001)	(Table	3).	A	separate	regression	
analysis	demonstrated	that	opioids,	diuretics,	anticholinergics,	SNRIs	and	SSRIs	medications	
were	not	statistically	significant	in	predicting	symptoms	(Burge-4	score).	
	
Table	3.	Multiple	linear	regression	analysis	of	the	impedance	index	(H2/R)	
Variable	 Beta	(standard	error)	 P	
Constant	 96.96	(10.02)	 <0.001	
Age	 0.13	(0.11)	 0.246	
Female	 -13.85	(2.52)	 <0.001	
ECOG	 -0.55	(1.38)	 0.692	
Oedema	present	 10.94	(2.89)	 <0.001	
Urea:creatinine	ratio	 -0.02	(0.02)	 0.423	
Morita	Dehydration	Score	 -2.55	(1.1)	 0.023	
Burge-4	score	 -0.29	(0.14)	 0.038	
R	 0.71	 	
R	squared	 0.50	 	
Adjusted	R	squared	 0.45	 	
Standard	error	of	estimate	 11.38	 	
Durbin-Watson	 1.74	 	
No.	of	observations	 90	 	
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Table	3	shows	the	multiple	linear	regression	analysis	to	model	the	relationship	between	the	
impedance	index	(H2/R)	and	predictor	variables	(age,	gender,	Morita	Dehydration	Score,	
oedema	presence,	urea:creatinine	ratio	and	the	Burge-4	score).		
	
	
Hydration	assessment	and	BIVA		
Hydration	status	was	normal	in	43	(47.8%),	‘more-hydrated’	in	37	(41.1%)	and	‘less	
hydrated’	in	10	(11.1%)	(Fig	3	and	4;	Table	4).	We	simplified	the	hydration	status	
classifications	to	compare	‘less-hydrated’	participants	(n	=10,	11.1%)	to	those	‘not	less	
hydrated’	(n	=	80,	88.9%).	This	comparison	demonstrated	that	oral	fluid	intake	was	
statistically	significantly	lower	in	‘less	hydrated’	participants	compared	to	those	‘not	less	
hydrated’	(p=0.04)	(Table	5).	Additionally,	axilla	dryness	scored	significantly	higher	in	those	
‘less	hydrated’	compared	to	those	‘not	less	hydrated’	(p=	0.02).	No	other	statistically	
significant	differences	were	detected	for	the	current	sample.	The	analysis	demonstrated	
non-significant	differences	between	the	groups,	with	‘less	hydrated’	individuals	reporting	
higher	values	(when	compared	to	the	‘not	less	hydrated’	group)	for	symptoms	(the	Burge-4	
sub-scores),	the	Morita	Dehydration	Score,	the	ur:cr	ratio,	urinary	osmolality	and	ECOG.		
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Fig	3.	Vector	positions	for	males	on	the	RXc	point	graph	(N=42)	
	
Values	for	male	participants	are	illustrated	by	circles	on	the	50%,	75%,	and	95%	
bioimpedance	tolerance	ellipses	of	the	reference	population.	
	
Fig	4.	Vector	positions	for	females	on	the	RXc	point	graph	(N=48)		
	
Values	for	female	participants	are	illustrated	by	triangles	on	the	50%,	75%,	and	95%	
bioimpedance	tolerance	ellipses	of	the	reference	population.	
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Table	4.	Classification	of	hydration	as	a	three-item	scale	according	to	the	RXC	graph	scale		
Hydration	status	 Male	 Female	 Total	(%)	
Normal	 18	 25	 43	(47.8)	
‘Less	hydrated’	 7	 3	 10	(11.1)	
‘More	hydrated’	 17	 20	 37	(41.1)	
Total	 42	 48	 90	
Table	4	shows	the	hydration	status	of	participants	according	to	the	position	of	individual	
vectors	on	the	RXc	graph	scale.	
	
Table	5.	Comparison	between	‘less	hydrated’	and	‘not	less	hydrated’	groups			
	 ‘Less	hydrated’	(n=10)	 	 ‘Not	less	hydrated’	(n=80)	 	 	
Variable	 Mean	 SD	 	 Mean	 SD	 T	test	 p	
Burge-4	score	(mm)	 257.60	 91.76	 	 217.63	 95.47	 1.25	 0.21	
	 Thirst	 72.70	 22.97	 	 54.04	 29.67	 1.92	 0.06	
	 Dry	mouth	 70.60	 25.80	 	 58.69	 31.07	 1.16	 0.25	
	 Unpleasant	taste	 52.20	 37.51	 	 41.11	 33.71	 0.97	 0.34	
	 Fatigue	 62.10	 23.73	 	 63.79	 30.92	 -0.17	 0.87	
Ur:Cr	ratio	(mmol/mmol)	 137.15	 101.33	 	 91.62	 42.20	 1.41	 0.19	
Na	(mmol/L)	(n=89)	 134.10	 4.77	 	 136.38	 4.17	 -1.60	 0.11	
eGFR	(mL/min/1.73m2)	 71.00	 24.68	 	 72.24	 18.09	 -0.20	 0.85	
AdjCa	(mmol/L)	(n=61)	 2.26	 0.13	 	 2.32	 0.25	 -0.81	 0.42	
Serum	osmalilty	(mosm/kg)	 281.75	 18.46	 	 286.68	 9.38	 -0.95	 0.35	
Albumin	(g/L)	 29.70	 3.95	 	 32.36	 6.25	 -1.31	 0.19	
Urine	osmolality	(mosm/kg)	(n=61)	 540.50	 177.03	 	 505.39	 212.25	 0.31	 0.76	
H2/R		(m2/Ohm)	 39.57	 9.28	 	 53.08	 15.40	 -2.71	 0.008	
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Mann	U	Whitney	test	variable	 Mean	 Rank	 	 Mean	 Rank	 Z	 P	
ECOG	 52.90	 529.00	 	 44.58	 3566.00	 326	 0.32	
Oral	intake	(mLs)	 31.25	 312.5	 	 47.28	 3782.50	 257.5	 0.04	
Morita	Dehydration	Score	 58.60	 586.00	 	 43.86	 3509.00	 269	 0.08	
	 Mucous		 52.45	 524.50	 	 44.63	 3570.50	 330.5	 0.34	
	 Axilla	dryness	 61.00	 610.00	 	 43.56	 3485.00	 245	 0.02	
	 Sunken	eyes	 44.90	 449.00	 	 45.58	 3646.00	 394	 0.92	
Table	5	shows	a	comparison	between	the	‘less	hydrated’	and	the	‘not	less	hydrated’	groups	
according	to	symptoms	(Burge-4	score),	biochemical	measures,	performance	status	(ECOG),	
oral	fluid	intake	and	physical	symptoms	(Morita	Dehydration	Score).	
	
Survival	analysis		
Seventy-six	(84.4%)	participants	died	before	the	end	of	the	follow-up	period.	Median	
survival	for	the	sample	was	62	days	(Table	6).	Median	survival	was	shortest	in	‘less	
hydrated’	participants	(44	days)	and	longest	in	those	‘more	hydrated’	(70	days).	Survival	was	
statistically	significantly	shorter	when	‘less	hydrated’	participants	were	compared	to	those	
‘not	less	hydrated’	(44	days	vs.	68	days,	hazard	ratio	=	2.01	[95%	Confidence	Interval	(CI)	=	
1.00,	4.02];	p=0.049)	(Fig	5).	Participants	with	pre-renal	failure	had	shorter	survival	when	
compared	to	those	without	pre-renal	failure	(44	days	vs.	100	days,	hazard	ratio	=	2.03	
[95%CI=	1.26,	3.26];	p=0.003)	(Fig	6).		
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Table	6.	Univariate	survival	analysis	of	participants	according	to	hydration	status	and	pre-
renal	failure	classifications	
Subgroup	 Median	survival	in	days		 Hazard	ratio	
(95%	CI)	
p	
Overall	 62.0		 	 	
Hydration	classification	according	to	three	BIVA	
classifications	
	 	 	
Normal	 68.0		 1.00	(ref)	 0.09	
‘Less	hydrated’	 44.0		 2.01	(1.00,	
4.02)	
0.11	
‘More	hydrated’	 70.0		 0.72	(0.45,	
1.15)	
0.34	
Hydration	classification	according	to	two	BIVA	
classifications	
	 	 	
‘Not	less	hydrated’	 68.0		 1.00	(ref)	 	
‘Less	hydrated’	 44.0		 2.01	(1.00,	
4.02)	
0.049	
Pre-renal	failure	present?	 	 	 	
No	 100.0		 1.00	(ref)	 	
Yes	 44.0		 2.03	(1.26,	
3.26)	
0.003	
Table	6	shows	the	survival	analysis	data	for	participants	according	to	hydration	status	and	
pre-renal	failure	classifications.	
	
The	H2/R	and	the	ur:cr	ratio	remained	significant	predictors	of	survival	following	statistical	
adjustment	(cox	regression)	for	age,	sex,	baseline	ECOG	performance	status	and	cancer	type	
(Table	7).	Cancer	type	also	significantly	influenced	survival	p=0.02.	The	hazard	ratio	for	
death	according	to	the	H2/R	was	0.98	[95%CI=	0.96,	1.00]	(p=	0.04);	this	means	each	unit	
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m2/Ohm	increase	of	the	H2/R	was	associated	with	reduced	probability	of	death	by	a	factor	
of	1.02	(i.e.	1/hazard	ratio).	The	hazard	ratio	for	death	according	to	the	ur:cr	ratio	was	1.01	
[95%CI=	1.00,	1.02],	p=0.001;	this	means	that	each	unit	increase	(mmol:mmol)	of	the	ur:cr	
ratio	was	associated	with	an	increased	probability	of	death	by	a	factor	of	0.99.	
	
Table	7.	Multivariate	cox	regression	analysis	for	death	according	to	age,	performance	
status,	cancer	type,	the	ur:cr	and	the	H2/R	
Variable	 Hazard	Ratio	(95%	CI)	 p	
Age	(years)	 0.99	(0.97,	1.02)	 0.52	
Female	 0.84	(0.47,	1.51)	 0.56	
ECOG	1	 	 0.06	
ECOG	(2	vs.	1)	 1.69	(0.72,	3.96)	 0.23	
ECOG	(3	vs.	1)	 2.82	(1.22,	6.54)	 0.02	
ECOG	(4	vs.	1)	 3.07	(1.17,	8.07)	 0.02	
Cancer	type	(GI)	 	 0.02	
Cancer	type	(Gyne	vs.	GI)	 0.40	(0.13,	1.24)	 0.11	
Cancer	type	(Lung	vs.	GI)	 1.35	(0.67,	2.75)	 0.41	
Cancer	type	(Misc	vs.	GI)	 0.41	(0.20,	0.83)	 0.01	
Cancer	type	(GU	vs	GI)	 0.42	(0.18,	1.00)	 0.05	
Ur:Cr	(mmol/mmol)	 1.01	(1.00,	1.02)	 0.001	
H2/R		(m2/Ohm)	 0.98	(0.96,	1.00)	 0.04	
Table	7	shows	the	cox	regression	analysis	for	death	(hazard	ratio)	according	to	age,	
performance	status	(ECOG),	cancer	type,	the	ur:cr	and	H2/R.	Abbreviations:	GI	=	
gastrointestinal;	Gyne	=	gynecological;	Misc	=	miscellaneous;	GU	=	genitourinary.	
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Fig	5.	Kaplan-Meier	graph	showing	survival	time	in	days	according	to	the	‘less	hydrated’	
classification	(χ2=4.08,	P=0.04)	
	
Tick	marks	indicate	censoring	of	data.		
Fig	6.	Kaplan-Meier	graph	showing	survival	time	in	days	according	to	the	presence	or	
absence	of	pre-renal	failure	(χ2=8.99,	P=0.003)	
	
Tick	marks	indicate	censoring	of	data.		
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Discussion	
Main	findings	and	new	knowledge	
This	is	the	first	study	to	use	BIVA	to	evaluate	hydration	and	its	relationship	with	symptoms	
and	survival	in	advanced	cancer	patients.	The	findings	demonstrate	that	hydration	(as	
measured	by	H2/R	and	BIVA)	in	advanced	cancer	was	significantly	associated	with	physical	
signs	(mucous	membrane	moisture,	axilla	dryness,	sunken	eyes,	oedema),	symptoms	(dry	
mouth,	thirst,	unpleasant	taste,	fatigue)	and	oral	fluid	intake.	Survival	was	statistically	
significantly	shorter	in	‘less-hydrated’	individuals	and	those	with	pre-renal	failure.		
Comparison	with	previous	work	
Our	data	demonstrates	that	the	Morita	Dehydration	Score	was	associated	with	hydration	
status,	which	supports	previous	work	using	this	tool	to	assess	physical	signs	of	
hydration.[32]	In	this	study,	women	had	a	lower	H2/R	compared	to	men,	which	suggests	
comparatively	lower	hydration	volume.	This	finding	is	consistent	with	previous	work[6,	51]	
and	human	physiology,[6,	51,	58,	59]	as	women	normally	have	more	body	fat	than	men	and	
therefore	comparatively	have	less	body	water	in	proportion	to	their	weight.[58,	59]	
Oedematous	participants	had	higher	H2/R	compared	to	non-oedematous	participants,	which	
suggests	they	had	an	increased	hydration	volume.	Although	these	findings	are	consistent	
with	the	literature	it	is	not	possible	to	determine	intracellular	or	extracellular	volumes	
without	the	use	of	regression	equations;	however,	these	equations	have	methodological	
limitations	in	advanced	cancer.[24,	25,	60-62]	
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Our	study	demonstrates	how	higher	Burge-4	scores	were	associated	with	lower	H2/R	(which	
suggests	comparatively	lower	TBW	volume).	Consequently,	our	data	supports	previous	work	
concerning	the	assessment	of	dehydration	symptoms	in	advanced	cancer[36,	40]	and	non-
cancer	populations.[63-67]	Our	analysis	demonstrates	that	lower	oral	fluid	intake	was	
associated	with	‘less	hydrated’	patients.	However,	we	are	unable	to	determine	whether	this	
reduction	in	oral	intake	contributed	to	the	participant’s	hydration	volume,	or	if	it	was	the	
result	of	their	clinical	condition.		
Previous	estimates	of	cancer	dehydration	prevalence	are	generally	based	on	biochemical	
criteria	with	the	prevalence	reported	to	be	60-75%.[68,	69]	In	this	study,	only	11.1%	of	
participants	were	‘less-hydrated’	and	41.1%	were	‘more	hydrated’.	Comparatively,	the	
prevalence	of	pre-renal	failure	in	this	study	was	41.1%,	which	is	consistent	with	previous	
work.[54]	Our	findings	demonstrated	that	(in	this	sample)	individuals	were	more	likely	to	be	
‘more	hydrated’	as	opposed	to	‘less	hydrated’.	This	may	suggest	that	biochemical	
definitions	of	dehydration	lack	sensitivity	in	people	with	advanced	cancer.	Furthermore,	the	
regression	analysis	did	not	detect	a	statistically	significant	association	between	the	ur:cr	
ratio	and	the	H2/R	variables	(Table	3).	This	data	supports	previous	work	that	demonstrates	
how	biochemical	measures	poorly	correlate	with	symptoms	(dry	mouth,	thirst,	fatigue	and	
unpleasant	taste)	in	advanced	cancer.[2,	3,	33,	53,	69,	70]	This	provides	evidence	that	
biochemical	measures	lack	sensitivity	to	predict	hydration-related	symptoms	in	advanced	
cancer.		
Survival	
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Our	data	demonstrates	that	pre-renal	failure	was	associated	with	shorter	survival	in	patients	
with	advanced	cancer,	which	is	consistent	with	previous	research.[71]	Similarly,	the	
Prognosis	in	Palliative	care	Study	(PiPS)	reported	how	an	elevated	urea	measurement	was	a	
predictor	of	shorter	survival	in	patients	with	advanced	cancer.[72]	We	are	unable	to	
determine	the	exact	reason	for	the	association	of	shorter	survival	with	lower	H2/R	and	BIVA	
hydration	status.	However,	it	is	possible	that	‘less	hydrated’	individuals	were	more	likely	to	
have	a	clinical	picture	that	was	associated	with	shorter	survival	(e.g.	cachexia).		
Limitations	
This	study	describes	a	small,	predominantly	Caucasian,	specialist	palliative	care	population	
in	the	last	two	months	of	life.	Only	ten	participants	were	‘less	hydrated’,	which	meant	that	
the	two-group	analysis	was	statistically	limited.	Consequently,	the	ability	to	extrapolate	the	
results	of	this	analysis	to	other	population	groups	is	limited.	This	study	was	observational	
and	therefore	is	unable	to	determine	causation	of	the	studied	variables.	This	analysis	
involved	many	different	cancers	at	various	stages	of	illness.	Survival	was	significantly	
influenced	by	cancer	type,	meaning	some	participants	experienced	shorter	survival	on	
account	of	their	diagnosis.	Consequently,	the	exact	influence	of	hydration	on	survival	is	
difficult	to	determine.	Furthermore,	it	is	possible	that	pre-existing	differences	(related	to	
the	different	cancers)	may	have	caused	variation	in	the	body	composition	of	participants.	
Although	the	H2/R	is	the	single	best	predictor	of	TBW	we	are	unable	estimate	fluid	volume	
without	the	use	of	regression	equations	(which	improve	the	accuracy	of	TBW	measurement	
but	are	methodologically	limited	in	cancer).	Additionally,	the	BIVA	method	is	unable	to	
distinguish	between	fluid	compartments	or	define	intracellular	and	extracellular	fluid	
volumes,	which	limits	our	ability	to	study	these	differences	in	greater	detail.		
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What	is	the	significance	of	the	findings	of	this	analysis?		
This	analysis	provides	evidence	that	hydration	status	is	related	to	physical	signs	(mucous	
membrane	moisture,	axilla	dryness,	sunken	eyes,	oedema),	symptoms	(dry	mouth,	thirst,	
unpleasant	taste,	fatigue),	oral	fluid	intake	and	survival	in	an	advanced	cancer	population.	
These	variables	can	potentially	be	used	to	develop	criteria	for	the	assessment	of	hydration	
status,	for	the	purposes	of	research	and	clinical	practice.	Our	data	reports	no	statistically	
significant	association	between	biochemical	measures	and	hydration	status.	Furthermore,	
we	report	that	(in	this	sample)	a	greater	number	of	participants	were	‘more-hydrated’	
compared	to	those	‘less-hydrated’.	Consequently,	we	recommend	that	healthcare	
professionals	should	carefully	assess	hydration	status	in	their	patients;	it	may	be	possible	for	
individuals	to	be	at	risk	of	fluid	overload	even	though	the	biochemical	results	indicate	pre-
renal	failure.	However,	we	are	unable	to	provide	recommendations	for	the	use	(or	non	use)	
of	CAH	as	this	was	beyond	the	scope	of	this	research	study.		
Future	opportunities	and	research	possibilities		
Future	studies	can	build	on	this	work	and	use	BIVA	to	study	hydration	status	according	to	
specific	cancers,	stratified	by	performance	status,	stage	of	illness,	ethnicity	and	gender.	The	
non-invasive	properties	of	BIVA	provide	the	potential	to	conduct	longitudinal	assessments	
to	study	hydration	and	symptoms	over	time	[28]	(e.g.	the	dying	phase),	in	order	to	
determine	the	clinical	utility	of	CAH.	Further	studies	can	examine	the	potential	use	of	
bioimpedance	for	prognostication.		
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Conclusions		
In	advanced	cancer,	hydration	status	(classified	by	BIA/BIVA)	relates	to	clinically	measurable	
signs	and	symptoms.	Hydration	status	and	pre-renal	failure	were	independent	predictors	of	
survival.	Further	studies	can	establish	the	utility	of	BIVA	as	a	standardised	hydration	
assessment	tool	and	explore	its	potential	research	application,	in	order	to	inform	the	clinical	
management	of	fluid	balance	in	patients	with	advanced	cancer.	
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Committee	–	West	(Local	research	ethics	committee	approval	number	=	12/WA/0200).	The	
study	was	sponsored	by	the	University	of	Liverpool.	The	researchers	were	independent	from	
funders	and	sponsors.	The	sponsors	and	funder	did	not	have	access	to	the	data	or	a	role	in	
the	data	analysis,	results	interpretation	or	writing	the	manuscript.	
Supporting	Information	
S1	Dataset.	Minimal	anonymized	dataset	for	the	study	findings.	
			
31	
References	
1.	 Cerchietti	L,	Navigante	A,	Sauri	A,	Palazzo	F.	Hypodermoclysis	for	control	of	dehydration	in	
terminal-stage	cancer.	IntJPalliatNurs.	2000;6(8):370-4.	
2.	 Nwosu	AC,	Mayland	CR,	Mason	SR,	Khodabukus	AF,	Varro	A,	Ellershaw	JE.	Hydration	in	
advanced	cancer:	can	bioelectrical	impedance	analysis	improve	the	evidence	base?	A	systematic	
review	of	the	literature.	J	Pain	Symptom	Manage.	2013;46(3):433-46.e6.	Epub	2012/12/04.	doi:	
10.1016/j.jpainsymman.2012.08.018.	PubMed	PMID:	23200189.	
3.	 Sarhill	N,	Walsh	D,	Nelson	K,	Davis	M.	Evaluation	and	treatment	of	cancer-related	fluid	
deficits:	volume	depletion	and	dehydration.	SupportCare	Cancer.	2001;9(6):408-19.	
4.	 Good	P,	Richard	R,	Syrmis	W,	Jenkins-Marsh	S,	Stephens	J.	Medically	assisted	hydration	for	
adult	palliative	care	patients.	The	Cochrane	database	of	systematic	reviews.	2014;4:CD006273.	Epub	
2014/04/25.	doi:	10.1002/14651858.CD006273.pub3.	PubMed	PMID:	24760678.	
5.	 Parkash	R,	Burge	F.	The	family's	perspective	on	issues	of	hydration	in	terminal	care.	
JPalliatCare.	1997;13(4):23-7.	
6.	 Piccoli	A,	Nigrelli	S,	Caberlotto	A,	Bottazzo	S,	Rossi	B,	Pillon	L,	et	al.	Bivariate	normal	values	
of	the	bioelectrical	impedance	vector	in	adult	and	elderly	populations.	AmJClinNutr.	1995;61(2):269-
70.	
7.	 Barbosa-Silva	MC,	Barros	AJ.	Bioelectrical	impedance	analysis	in	clinical	practice:	a	new	
perspective	on	its	use	beyond	body	composition	equations.	CurrOpinClinNutrMetab	Care.	
2005;8(3):311-7.	
8.	 Thomasset	A.	Bioelectrical	properties	of	tissue	impedance	measurements.	Lyon	Medical.	
1962;207:12.	Epub	118.	
9.	 Hoffer	EC,	Meador	CK,	Simpson	DC.	Correlation	of	whole-body	impedance	with	total	body	
water	volume.	J	Appl	Physiol.	1969;27(4):531-4.	Epub	1969/10/01.	PubMed	PMID:	4898406.	
10.	 Kushner	RF.	Bioelectrical	impedance	analysis:	a	review	of	principles	and	applications.	Journal	
of	the	American	College	of	Nutrition.	1992;11(2):199-209.	Epub	1992/04/01.	PubMed	PMID:	
1578098.	
11.	 Kushner	RF,	Schoeller	DA,	Fjeld	CR,	Danford	L.	Is	the	impedance	index	(ht2/R)	significant	in	
predicting	total	body	water?	Am	J	Clin	Nutr.	1992;56(5):835-9.	Epub	1992/11/01.	PubMed	PMID:	
1415001.	
12.	 Deurenberg	P,	van	der	Kooy	K,	Leenen	R,	Weststrate	JA,	Seidell	JC.	Sex	and	age	specific	
prediction	formulas	for	estimating	body	composition	from	bioelectrical	impedance:	a	cross-
			
32	
validation	study.	International	journal	of	obesity.	1991;15(1):17-25.	Epub	1991/01/01.	PubMed	
PMID:	2010255.	
13.	 Kushner	RF,	Schoeller	DA.	Estimation	of	total	body	water	by	bioelectrical	impedance	
analysis.	Am	J	Clin	Nutr.	1986;44(3):417-24.	Epub	1986/09/01.	PubMed	PMID:	3529918.	
14.	 Davies	PS,	Preece	MA,	Hicks	CJ,	Halliday	D.	The	prediction	of	total	body	water	using	
bioelectrical	impedance	in	children	and	adolescents.	Annals	of	human	biology.	1988;15(3):237-40.	
Epub	1988/05/01.	PubMed	PMID:	3389733.	
15.	 Deurenberg	P,	van	der	Kooij	K,	Evers	P,	Hulshof	T.	Assessment	of	body	composition	by	
bioelectrical	impedance	in	a	population	aged	greater	than	60	y.	Am	J	Clin	Nutr.	1990;51(1):3-6.	Epub	
1990/01/01.	PubMed	PMID:	2296928.	
16.	 Van	Loan	M,	Mayclin	P.	Bioelectrical	impedance	analysis:	is	it	a	reliable	estimator	of	lean	
body	mass	and	total	body	water.	Human	biology.	1987;59(2):299-309.	Epub	1987/04/01.	PubMed	
PMID:	3596569.	
17.	 Jackson	AS,	Pollock	ML,	Graves	JE,	Mahar	MT.	Reliability	and	validity	of	bioelectrical	
impedance	in	determining	body	composition.	Journal	of	applied	physiology	(Bethesda,	Md	:	1985).	
1988;64(2):529-34.	Epub	1988/02/01.	PubMed	PMID:	3372410.	
18.	 Nyboer	J.	Electrical	impedance	plethysmography.:	Oxford:	Blackwell	Scientific	Publications	
Ltd.	Springfield,	Illinois:	Charles	C.Thomas.;	1959.	
19.	 Simons	JP,	Schols	AM,	Westerterp	KR,	Ten	Velde	GP,	Wouters	EF.	Bioelectrical	impedance	
analysis	to	assess	changes	in	total	body	water	in	patients	with	cancer.	Clin	Nutr.	1999;18(1):35-9.	
Epub	1999/08/25.	doi:	10.1054/clnu.1998.0239.	PubMed	PMID:	10459080.	
20.	 Piccoli	A.	Bioelectric	impedance	measurement	for	fluid	status	assessment.	ContribNephrol.	
2010;164:143-52.	
21.	 McDonald	JJ,	Chanduvi	B,	Velarde	G,	Cama	R,	Diaz	F,	Carrillo	L,	et	al.	Bioimpedance	
monitoring	of	rehydration	in	cholera.	Lancet.	1993;341(8852):1049-51.	
22.	 Bozzetto	S,	Piccoli	A,	Montini	G.	Bioelectrical	impedance	vector	analysis	to	evaluate	relative	
hydration	status.	PediatrNephrol.	2009.	
23.	 Codognotto	M,	Piazza	M,	Frigatti	P,	Piccoli	A.	Influence	of	localized	edema	on	whole-body	
and	segmental	bioelectrical	impedance.	Nutrition.	2008;24(6):569-74.	
24.	 Nescolarde	L,	Piccoli	A,	Roman	A,	Nunez	A,	Morales	R,	Tamayo	J,	et	al.	Bioelectrical	
impedance	vector	analysis	in	haemodialysis	patients:	relation	between	oedema	and	mortality.	
Physiol	Meas.	2004;25(5):1271-80.	
25.	 Piccoli	A.	Bioelectric	impedance	vector	distribution	in	peritoneal	dialysis	patients	with	
different	hydration	status.	Kidney	Int.	2004;65(3):1050-63.	
			
33	
26.	 Pillon	L,	Piccoli	A,	Lowrie	EG,	Lazarus	JM,	Chertow	GM.	Vector	length	as	a	proxy	for	the	
adequacy	of	ultrafiltration	in	hemodialysis.	Kidney	Int.	2004;66(3):1266-71.	
27.	 Toso	S,	Piccoli	A,	Gusella	M,	Menon	D,	Crepaldi	G,	Bononi	A,	et	al.	Bioimpedance	vector	
pattern	in	cancer	patients	without	disease	versus	locally	advanced	or	disseminated	disease.	
Nutrition.	2003;19(6):510-4.	
28.	 Nwosu	AC,	Morris	L,	Mayland	C,	Mason	S,	Pettitt	A,	Ellershaw	J.	Longitudinal	bioimpedance	
assessments	to	evaluate	hydration	in	POEMS	syndrome.	BMJ	Support	Palliat	Care.	2016.	Epub	
2016/04/30.	doi:	10.1136/bmjspcare-2015-000991.	PubMed	PMID:	27125269.	
29.	 Toso	S,	Piccoli	A,	Gusella	M,	Menon	D,	Bononi	A,	Crepaldi	G,	et	al.	Altered	tissue	electric	
properties	in	lung	cancer	patients	as	detected	by	bioelectric	impedance	vector	analysis.	Nutrition.	
2000;16(2):120-4.	
30.	 Malecka-Massalska	T,	Smolen	A,	Zubrzycki	J,	Lupa-Zatwarnicka	K,	Morshed	K.	Bioimpedance	
vector	pattern	in	head	and	neck	squamous	cell	carcinoma.	JPhysiol	Pharmacol.	2012;63(1):101-4.	
31.	 World	Health	Organization.	International	Classification	of	Diseases	(ICD)	for	Oncology,	3rd	
Edition	(ICD-O-3).	2012.	
32.	 Morita	T,	Hyodo	I,	Yoshimi	T,	Ikenaga	M,	Tamura	Y,	Yoshizawa	A,	et	al.	Association	between	
hydration	volume	and	symptoms	in	terminally	ill	cancer	patients	with	abdominal	malignancies.	
AnnOncol.	2005;16(4):640-7.	
33.	 Gross	CR,	Lindquist	RD,	Woolley	AC,	Granieri	R,	Allard	K,	Webster	B.	Clinical	indicators	of	
dehydration	severity	in	elderly	patients.	JEmergMed.	1992;10(3):267-74.	
34.	 Eaton	D,	Bannister	P,	Mulley	GP,	Connolly	MJ.	Axillary	sweating	in	clinical	assessment	of	
dehydration	in	ill	elderly	patients.	BMJ.	1994;308(6939):1271.	
35.	 McGee	S,	Abernethy	WB,	III,	Simel	DL.	The	rational	clinical	examination.	Is	this	patient	
hypovolemic?	JAMA.	1999;281(11):1022-9.	
36.	 Burge	FI.	Dehydration	symptoms	of	palliative	care	cancer	patients.	JPain	SymptomManage.	
1993;8(7):454-64.	
37.	 Bruera	E,	Hui	D,	Dalal	S,	Torres-Vigil	I,	Trumble	J,	Roosth	J,	et	al.	Parenteral	hydration	in	
patients	with	advanced	cancer:	a	multicenter,	double-blind,	placebo-controlled	randomized	trial.	J	
Clin	Oncol.	2013;31(1):111-8.	Epub	2012/11/22.	doi:	10.1200/jco.2012.44.6518.	PubMed	PMID:	
23169523;	PubMed	Central	PMCID:	PMC3530688.	
38.	 Nakajima	N,	Hata	Y,	Kusumuto	K.	A	clinical	study	on	the	influence	of	hydration	volume	on	
the	signs	of	terminally	ill	cancer	patients	with	abdominal	malignancies.	J	Palliat	Med.	
2013;16(2):185-9.	Epub	2013/01/19.	doi:	10.1089/jpm.2012.0233.	PubMed	PMID:	23327196.	
			
34	
39.	 Oken	MM,	Creech	RH,	Tormey	DC,	Horton	J,	Davis	TE,	McFadden	ET,	et	al.	Toxicity	and	
response	criteria	of	the	Eastern	Cooperative	Oncology	Group.	Am	J	Clin	Oncol.	1982;5(6):649-55.	
Epub	1982/12/01.	PubMed	PMID:	7165009.	
40.	 Burge	F.	Dehydration	symptoms	of	palliative	care	cancer	patients:	McGill	University,	
Montreal;	1991.	
41.	 Twycross	R,	Wilcock	A.	Palliative	Care	Formulary	(PCF4):	Palliativedrugs.com	Ltd;	2011.	
42.	 Mercadante	S,	Caraceni	A.	Conversion	ratios	for	opioid	switching	in	the	treatment	of	cancer	
pain:	a	systematic	review.	Palliat	Med.	2011;25(5):504-15.	Epub	2011/06/29.	doi:	
10.1177/0269216311406577.	PubMed	PMID:	21708857.	
43.	 Boustani	M,	Campbell	N,	Munger	S,	Maidment	I,	Fox	C.	Impact	of	anticholinergics	on	the	
aging	brain:	A	review	and	practical	application.	Aging	Health.	2008;4(3):311-20.	
44.	 Campbell	N,	Boustani	M,	Limbil	T,	Ott	C,	Fox	C,	Maidment	I,	et	al.	The	cognitive	impact	of	
anticholinergics:	a	clinical	review.	Clin	Interv	Aging.	2009;4:225-33.	Epub	2009/06/26.	PubMed	
PMID:	19554093;	PubMed	Central	PMCID:	PMC2697587.	
45.	 Lukaski	HC,	Bolonchuk	WW,	Hall	CB,	Siders	WA.	Validation	of	tetrapolar	bioelectrical	
impedance	method	to	assess	human	body	composition.	J	Appl	Physiol.	1986;60(4):1327-32.	Epub	
1986/04/01.	PubMed	PMID:	3700310.	
46.	 Kyle	UG,	Bosaeus	I,	De	Lorenzo	AD,	Deurenberg	P,	Elia	M,	Gomez	JM,	et	al.	Bioelectrical	
impedance	analysis--part	I:	review	of	principles	and	methods.	Clin	Nutr.	2004;23(5):1226-43.	Epub	
2004/09/24.	doi:	10.1016/j.clnu.2004.06.004.	PubMed	PMID:	15380917.	
47.	 Kyle	UG,	Bosaeus	I,	De	Lorenzo	AD,	Deurenberg	P,	Elia	M,	Manuel	GJ,	et	al.	Bioelectrical	
impedance	analysis-part	II:	utilization	in	clinical	practice.	ClinNutr.	2004;23(6):1430-53.	
48.	 Gatignon	H.	Multivariate	Normal	Distribution.		Statistical	analysis	of	management	data:	
Springer;	2011.	p.	9-28.	
49.	 Piccoli	A,	Rossi	B,	Pillon	L,	Bucciante	G.	A	new	method	for	monitoring	body	fluid	variation	by	
bioimpedance	analysis:	the	RXc	graph.	Kidney	Int.	1994;46(2):534-9.	
50.	 Piccoli	A,	Brunani	A,	Savia	G,	Pillon	L,	Favaro	E,	Berselli	ME,	et	al.	Discriminating	between	
body	fat	and	fluid	changes	in	the	obese	adult	using	bioimpedance	vector	analysis.	IntJObesRelat	
Metab	Disord.	1998;22(2):97-104.	
51.	 Piccoli	A,	Pillon	L,	Dumler	F.	Impedance	vector	distribution	by	sex,	race,	body	mass	index,	
and	age	in	the	United	States:	standard	reference	intervals	as	bivariate	Z	scores.	Nutrition.	
2002;18(2):153-67.	
52.	 Lentner	C.	Introduction	to	statistics.	Statistical	tables.	Mathematical	formulae.	In:	Geigy	
scientific	tables.	8	ed:	Basel:	Ciba-Geigy	Limited;	1982.	1	p.	
			
35	
53.	 Morita	T,	Hyodo	I,	Yoshimi	T,	Ikenaga	M,	Tamura	Y,	Yoshizawa	A,	et	al.	Artificial	hydration	
therapy,	laboratory	findings,	and	fluid	balance	in	terminally	ill	patients	with	abdominal	malignancies.	
JPain	SymptomManage.	2006;31(2):130-9.	
54.	 Guo	Y,	Hainley	S,	Palmer	JL,	Bruera	E.	Azotemia	in	cancer	patients	during	inpatient	
rehabilitation.	AmJHospPalliatCare.	2007;24(4):264-9.	
55.	 Mukand	JA,	Cai	C,	Zielinski	A,	Danish	M,	Berman	J.	The	effects	of	dehydration	on	
rehabilitation	outcomes	of	elderly	orthopedic	patients.	Archives	of	physical	medicine	and	
rehabilitation.	2003;84(1):58-61.	
56.	 Armitage	P,	Berry	G,	Matthews	JNS.	Statistical	Methods	in	Medical	Research:	Wiley.	2008.	
57.	 Piccoli	A,	Pastori	G.	BIVA	software.	Department	of	Medical	and	Surgical	Sciences.	University	
of	Padova,	Padova,	Italy.	2002.	
58.	 Guyton	ACH,	J.	E.,.	Textbook	of	Medical	Physiology.	Tenth	edition	ed:	W.B	Saunders	
Company.	2000.	
59.	 Martinoli	R,	Mohamed	EI,	Maiolo	C,	Cianci	R,	Denoth	F,	Salvadori	S,	et	al.	Total	body	water	
estimation	using	bioelectrical	impedance:	a	meta-analysis	of	the	data	available	in	the	literature.	Acta	
Diabetol.	2003;40	Suppl	1:S203-6.	Epub	2003/11/18.	doi:	10.1007/s00592-003-0066-2.	PubMed	
PMID:	14618473.	
60.	 Piccoli	A.	Identification	of	operational	clues	to	dry	weight	prescription	in	hemodialysis	using	
bioimpedance	vector	analysis.	The	Italian	Hemodialysis-Bioelectrical	Impedance	Analysis	(HD-BIA)	
Study	Group.	Kidney	Int.	1998;53(4):1036-43.	
61.	 Piccoli	A,	Rossi	B,	Pillon	L,	Bucciante	G.	Body	fluid	overload	and	bioelectrical	impedance	
analysis	in	renal	patients.	Mineral	and	electrolyte	metabolism.	1996;22(1-3):76-8.	Epub	1996/01/01.	
PubMed	PMID:	8676831.	
62.	 Guglielmi	FW,	Mastronuzzi	T,	Pietrini	L,	Panarese	A,	Panella	C,	Francavilla	A.	The	RXc	graph	in	
evaluating	and	monitoring	fluid	balance	in	patients	with	liver	cirrhosis.	Ann	N	Y	Acad	Sci.	
1999;873:105-11.	Epub	1999/06/18.	PubMed	PMID:	10372157.	
63.	 Rolls	BJ,	Wood	RJ,	Rolls	ET,	Lind	H,	Lind	W,	Ledingham	JG.	Thirst	following	water	deprivation	
in	humans.	The	American	journal	of	physiology.	1980;239(5):R476-82.	Epub	1980/11/01.	PubMed	
PMID:	7001928.	
64.	 Wirth	JB,	Folstein	MF.	Thirst	and	weight	gain	during	maintenance	hemodialysis.	
Psychosomatics.	1982;23(11):1125-34.	doi:	http://dx.doi.org/10.1016/S0033-3182(82)73279-7.	
65.	 Engell	DB,	Maller	O,	Sawka	MN,	Francesconi	RN,	Drolet	L,	Young	AJ.	Thirst	and	fluid	intake	
following	graded	hypohydration	levels	in	humans.	Physiology	&	behavior.	1987;40(2):229-36.	Epub	
1987/01/01.	PubMed	PMID:	3306730.	
			
36	
66.	 McCorkle	R.	The	measurement	of	symptom	distress.	Seminars	in	Oncology	Nursing.	
1987;3(4):248-56.	doi:	http://dx.doi.org/10.1016/S0749-2081(87)80015-3.	
67.	 Phillips	PA,	Rolls	BJ,	Ledingham	JG,	Forsling	ML,	Morton	JJ,	Crowe	MJ,	et	al.	Reduced	thirst	
after	water	deprivation	in	healthy	elderly	men.	The	New	England	journal	of	medicine.	
1984;311(12):753-9.	Epub	1984/09/20.	doi:	10.1056/nejm198409203111202.	PubMed	PMID:	
6472364.	
68.	 Waller	A,	Hershkowitz	M,	Adunsky	A.	The	effect	of	intravenous	fluid	infusion	on	blood	and	
urine	parameters	of	hydration	and	on	state	of	consciousness	in	terminal	cancer	patients.	
AmJHospPalliatCare.	1994;11(6):22-7.	
69.	 Ellershaw	JE,	Sutcliffe	JM,	Saunders	CM.	Dehydration	and	the	dying	patient.	JPain	
SymptomManage.	1995;10(3):192-7.	
70.	 Rösler	A,	Lehmann	F,	Krause	T,	Wirth	R,	von	Renteln-Kruse	W.	Nutritional	and	hydration	
status	in	elderly	subjects:	Clinical	rating	versus	bioimpedance	analysis.	Archives	of	Gerontology	and	
Geriatrics.	2010;50(3):e81-e5.	doi:	http://dx.doi.org/10.1016/j.archger.2009.06.007.	
71.	 Humphreys	BD,	Soiffer	RJ,	Magee	CC.	Renal	Failure	Associated	with	Cancer	and	Its	
Treatment:	An	Update.	Journal	of	the	American	Society	of	Nephrology.	2005;16(1):151-61.	doi:	
10.1681/asn.2004100843.	
72.	 Gwilliam	B,	Keeley	V,	Todd	C,	Gittins	M,	Roberts	C,	Kelly	L,	et	al.	Development	of	prognosis	in	
palliative	care	study	(PiPS)	predictor	models	to	improve	prognostication	in	advanced	cancer:	
prospective	cohort	study.	BMJ.	2011;343:d4920.	Epub	2011/08/27.	doi:	10.1136/bmj.d4920.	
PubMed	PMID:	21868477;	PubMed	Central	PMCID:	PMC3162041.	
	
		
	
